Therapeutic | Gevokizumab |
Target | IL1B |
Heavy Chain | QVQLQESGPGLVKPSQTLSLTCSFSGFSLSTSGMGVGWIRQPSGKGLEWLAHIWWDGDESYNPSLKSRLTISKDTSKNQVSLKITSVTAADTAVYFCARNRYDPPWFVDWGQGTLVTVSS |
Light Chain | DIQMTQSTSSLSASVGDRVTITCRASQDISNYLSWYQQKPGKAVKLLIYYTSKLHSGVPSRFSGSGSGTDYTLTISSLQQEDFATYFCLQGKMLPWTFGQGTKLEIK |
100% seqID Fv Structure | 4g6k [Fvs: HL], 4g6m [Fvs: HL] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 4g6k [Fvs: HL] |
100% seqID Structure | 4g6m [Fvs: HL] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G2 |
Highest Clinical Trial (Aug '22) | Phase-III |
Estimated Status (Aug '22) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2010 |
INN Year Recommended | 2011 |
Companies Involved | IRIS, National Eye Institute, North Shore-Long Island Jewish Health System, Novartis, Servier, University of Zurich, XOMA |
Conditions Approved | na |
Conditions Active | Uveitis, Acne vulgaris, Acute coronary syndromes, Diabetic nephropathies, Giant cell arteritis, Labyrinthitis, Myositis, Osteoarthritis, Schnitzler syndrome, Scleritis, Colorectal cancer, Renal cell carcinoma |
Conditions Discontinued | Rheumatoid arthritis, Cancer, Gout, Juvenile rheumatoid arthritis, Type 1 diabetes mellitus, Type 2 diabetes mellitus, Pyoderma |
Notes |
SAbDab papers
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]
Thera-SAbDab paper
Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]